Recent Finacing
Recent Raise
Theolytics is an Oxford-based biotech developing oncolytic adenovirus therapies using phenotypic screening and bioselection platforms to create IV-compatible candidates—lead program THEO-260 targets ovarian cancer (IV/IP) entering Phase 1.
